The company is in the process of being taken private by Sycamore Partners in a deal that is expected to close in the fourth quarter of this year.

Cencora, Inc. COR is well-poised for growth on the back of robust U.S. Healthcare Solutions business and product launches.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cencora (COR – Research Report) and Johnson ...

BofA analyst Allen Lutz raised the firm’s price target on Cencora (COR) to $285 from $270 and keeps a Neutral rating on the shares. The recent ...

But Walgreens made $1 billion in profit by cashing out early on some of its shares of Cencora, a pharmaceutical solutions organization, and benefiting from gains from its investment in ...